{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:41:45Z","timestamp":1787013705591,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Forensic Sciences"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this study was to investigate the incidence of benzodiazepines in opioid\u2010positive death investigations, including trends in frequency and combination of drugs, as well as demographic data and blood concentrations, where available. Additionally, naloxone concentrations in polysubstance compared to opioid\u2010only cases were analyzed. This was a retrospective study that consisted of all post\u2010mortem toxicology cases in Ontario, Canada, from January 01, 2017, to December 31, 2021, with an opioid finding in any analyzed autopsy specimen. There were 11,033 death investigations identified. The overall rate of benzodiazepine co\u2010involvement was 54.5%. Males accounted for the majority of cases (71%), and the most affected age group was 30\u2010 to 39\u2010year\u2010olds. The most frequently detected opioid was fentanyl and the most frequently detected benzodiazepine was etizolam, which was also the most frequently observed opioid\/benzodiazepine combination. Findings related to differences in concentrations of opioids when naloxone was also present were mostly non\u2010significant, except for methadone. The rate of benzodiazepine detection with opioids grew faster than opioid detections overall, potentially due to the increasingly toxic drug supply. Detection of novel psychoactive drugs fluctuated more unpredictably than opioids and benzodiazepines associated with clinical use. These findings can help inform policy decisions by public health agencies in exploring harm reduction efforts, for example, education and drug\u2010checking services.<\/jats:p>","DOI":"10.1111\/1556-4029.15463","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T22:48:22Z","timestamp":1706482102000},"page":"607-617","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and blood concentrations of benzodiazepines and opioids in opioid\u2010positive death investigations in Ontario, Canada, from 2017 to 2021"],"prefix":"10.1111","volume":"69","author":[{"given":"Cora","family":"Mocanu","sequence":"first","affiliation":[{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Woodall","sequence":"additional","affiliation":[{"name":"University of Toronto Mississauga  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5123-6991","authenticated-orcid":false,"given":"Patricia","family":"Solbeck","sequence":"additional","affiliation":[{"name":"Quality Assurance Unit Centre of Forensic Sciences  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.18356\/9789210001212"},{"key":"e_1_2_9_3_1","volume-title":"Opioid\u2010 and stimulant\u2010related harms in Canada January 2016 to December 2021","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2022"},{"key":"e_1_2_9_4_1","unstructured":"Public Health Agency of Canada.Analyzed drug report. Drug Analysis Service [cited 2022 Dec 8]. Available from:https:\/\/health\u2010infobase.canada.ca\/drug\u2010analysis\u2010service\/analyzed\u2010drug\u2010report.html?p=CA&y=2021&q=all"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.38.6.02"},{"key":"e_1_2_9_6_1","unstructured":"Lach\u2010AidelbaumM.Why is Canada's illicit drug supply so deadly and what's being done about it? CBC News. 2022 Mar 18 [cited 2024 Jan 11]. Available from:https:\/\/www.cbc.ca\/news\/canada\/canada\u2010illicit\u2010drug\u2010supply\u2010explainer\u20101.6361623"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103169"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12889\u2010021\u201011757\u2010x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkab106"},{"key":"e_1_2_9_10_1","volume-title":"Global SMART update","author":"United Nations Office on Drugs and Crime","year":"2016"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx031"},{"key":"e_1_2_9_12_1","unstructured":"United Nations Office on Drugs and Crime.Data from the UNODC Early Warning Advisory on new psychoactive substances[cited 2022 Dec 8]. Available from:https:\/\/www.unodc.org\/unodc\/en\/scientists\/ewa\/data.html"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.05.018"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108300"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360\u20100443.1999.9479612.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/65.1.107"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102044.1983.tb13941.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102044.1983.tb14083.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.004"},{"issue":"6450","key":"e_1_2_9_20_1","first-page":"964","article-title":"Intravenous benzodiazepine abuse","volume":"289","author":"Strang J","year":"1984","journal-title":"Br Med J"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2019.1698587"},{"key":"e_1_2_9_22_1","volume-title":"Preliminary patterns in circumstances surrounding opioid\u2010related deaths in Ontario during the COVID\u201019 pandemic","author":"Ontario Drug Policy Research Network","year":"2020"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12731"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S265901"},{"key":"e_1_2_9_25_1","unstructured":"University of Utah Health Poison Control.Flumazenil.2022[cited 2022 Dec 9]. Available from:https:\/\/poisoncontrol.utah.edu\/news\/2022\/02\/flumazenil"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1081\/clt\u2010120030946"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2019.05.133"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S298607"},{"key":"e_1_2_9_29_1","unstructured":"Ontario Harm Reduction Network.The shifting unregulated drug supply in Ontario: implications and messaging regarding benzodiazepine\u2010type substances in drugs sold as opioids or \u201cdown\u201d[cited 2022 Dec 8]. Available from:https:\/\/ohrn.org\/wp\u2010content\/uploads\/2021\/05\/Benzodiazepines\u2010in\u2010the\u2010unregulated\u2010drug\u2010supply\u2010in\u2010Ontario_OHRN_\u2010March\u20102020.pdf"},{"key":"e_1_2_9_30_1","unstructured":"BC Emergency Health Services.Administration of intramuscular naloxone for suspected or confirmed opioid vverdose[cited 2022 Dec 9]. Available from:http:\/\/www.bcehs.ca\/about\u2010site\/Documents\/Naloxone%20reference%20guide%20for%20first%20responders.pdf"},{"key":"e_1_2_9_31_1","unstructured":"Government of Canada.Naloxone[cited 2022 Dec 8]. Available from:https:\/\/www.canada.ca\/en\/health\u2010canada\/services\/opioids\/naloxone.html"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkab079"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A226"},{"key":"e_1_2_9_34_1","unstructured":"Toronto's Drug Checking Service[cited 2022 Dec 9]. Available from:https:\/\/drugchecking.cdpe.org\/"},{"key":"e_1_2_9_35_1","volume-title":"Canadian drug summary: opioids","author":"Canadian Centre on Substance Use and Addiction","year":"2022"},{"key":"e_1_2_9_36_1","unstructured":"British Columbia Centre on Substance Use.2021[cited 2023 May 19]. Available from:https:\/\/drugcheckingbc.ca\/dashboard\/"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.01.005"},{"key":"e_1_2_9_38_1","volume-title":"Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020","author":"Liu S","year":"2021"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15365"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1948558"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1263139"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954\u2010020\u201000370\u20107\/metrics"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","unstructured":"FriesenEL KurdyakPA GomesT KollaG LeeceP ZhuL et\u00a0al.The impact of the COVID\u201019 pandemic on opioid\u2010related harm in Ontario. Science briefs of the Ontario COVID\u201019 Science Advisory Table.2021;2(42).https:\/\/doi.org\/10.47326\/ocsat.2021.02.42.1.0","DOI":"10.47326\/ocsat.2021.02.42.1.0"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1520\/JFS13791J"}],"container-title":["Journal of Forensic Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1556-4029.15463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:26:01Z","timestamp":1710318361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1556-4029.15463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/1556-4029.15463"],"URL":"https:\/\/doi.org\/10.1111\/1556-4029.15463","archive":["Portico"],"relation":{},"ISSN":["0022-1198","1556-4029"],"issn-type":[{"value":"0022-1198","type":"print"},{"value":"1556-4029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"2023-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}